Form 4: Pliant Therapeutics Chief Medical Officer Reports Stock and Option Awards

Pliant Therapeutics' Chief Medical Officer, Eric Lefebvre, received stock units and options, as detailed in a recent SEC Form 4 filing.

Summary

• Eric Lefebvre, Chief Medical Officer of Pliant Therapeutics, was granted 45,650 restricted stock units and options to purchase 91,300 shares of common stock.
• The restricted stock units vest in three equal annual installments starting January 16, 2025.
• The stock options vest monthly starting January 1, 2025, over a period of 48 months.
• The exercise price for the stock options is $11.14 per share.
• These transactions were reported in a Form 4 filing with the SEC on January 27, 2025.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock and options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock and option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard compensation practices for executives in publicly traded biotech companies.
• The vesting schedules are typical, with both time-based and performance-based vesting being common.
• The exercise price of $11.14 is relevant to the current market price of the stock at the time of the grant, which is not specified in the document.

Stakeholder Impact

• Shareholders may view the stock and option grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Pliant Therapeutics, Eric Lefebvre, stock options, restricted stock units, SEC Form 4, insider trading, executive compensation, vesting